Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the VIPOR regimen (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in central nervous system–involved diffu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Lymphoma with Secondary Involvement of the Central Nervous System
• Diffuse Large B-cell Lymphoma of the Central Nervous System

Drugs mentioned

• Gazyva (Obinutuzumab)
• IMBRUVICA (IBRUTINIB)
• PREDNISONE (Prednisone)
• Revlimid (lenalidomide)
• Venclexta (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-20